标题
Current therapies for lowering lipoprotein (a)
作者
关键词
-
出版物
JOURNAL OF LIPID RESEARCH
Volume 57, Issue 9, Pages 1612-1618
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2015-12-05
DOI
10.1194/jlr.r053066
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
- (2015) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic PatientsSignificance
- (2015) Mikaël Croyal et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance
- (2015) Raul D. Santos et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans
- (2015) Nike Müller et al. JOURNAL OF LIPID RESEARCH
- Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
- (2015) Romain Capoulade et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Dramatic lowering of very high Lp(a) in response to niacin
- (2014) Min Li et al. Journal of Clinical Lipidology
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular prevention—end of the road for niacin?
- (2014) Sony Tuteja et al. Nature Reviews Endocrinology
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial
- (2014) Todd J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers
- (2014) Benoit J. Arsenault et al. PLoS One
- Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
- (2013) Giuseppe Danilo Norata et al. EUROPEAN HEART JOURNAL
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
- (2013) John J. Albers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
- (2013) Ana Cenarro et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Screening for and Management of Elevated Lp(a)
- (2013) Michael B. Boffa et al. Current Cardiology Reports
- Emerging therapeutic agents to lower lipoprotein (a) levels
- (2012) Brian Kolski et al. CURRENT OPINION IN LIPIDOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
- (2012) Kiyohito Arai et al. JOURNAL OF LIPID RESEARCH
- Nicotinic acid inhibits hepaticAPOAgene expression: studies in humans and in transgenic mice
- (2012) Indumathi Chennamsetty et al. JOURNAL OF LIPID RESEARCH
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
- (2011) Michael H. Davidson et al. Journal of Clinical Lipidology
- Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
- (2011) Esther Merki et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Management of Lp(a)
- (2010) W. Virgil Brown et al. Journal of Clinical Lipidology
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes
- (2009) Alexander E. Fraley et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
- (2009) Beate R Jaeger et al. Nature Reviews Cardiology
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
- (2009) Robert Clarke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Action of Niacin
- (2008) Vaijinath S. Kamanna et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective Data
- (2008) Anna Bennet ARCHIVES OF INTERNAL MEDICINE
- Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume
- (2008) Seung Hyuk Choi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
- (2008) Frederick F Samaha et al. Nature clinical practice. Cardiovascular medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now